ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0511

Biomimetic Platform for Quantitative Drug Screening of Podocyte Cytoskeletal Dynamics and Morphology

Session Information

Category: Bioengineering

  • 300 Bioengineering

Authors

  • Bhattacharya, Smiti, Columbia University, New York, New York, United States
  • Haydak, Jonathan C., Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Stern, Alan, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Wiener, Robert, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Wong, Nicholas Joseph, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Defronzo, Stefanie, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Iyengar, Ravi, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Gordon, Ronald, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Costa, Kevin D., Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • He, John Cijiang, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Hone, James C., Columbia University, New York, New York, United States
  • Azeloglu, Evren U., Icahn School of Medicine at Mount Sinai, New York, New York, United States
Background

Foot process effacement is driven by dysregulation of cytoskeletal dynamics. Currently, there are no drugs that primarily target the podocyte cytoskeleton due to dearth of in vitro model systems. To address this limitation, we designed a 3D drug discovery platform with a morpho-mimetic milieu that allows high-throughput quantitative measurements of drug-induced cytoskeletal changes in podocytes.

Methods

Immortalized human podocytes were differentiated on micropatterned surfaces fabricated via photolithography. High-resolution microscopy including confocal, TIRF, SEM and atomic force microscopy (AFM) were used to characterize morphometric and biophysical properties. Protein expression was quantified using automated immunofluorescence, cell proliferation via EdU, and basal motility via fluorescent live-cell imaging. High-throughput analytical capabilities of the system were tested with cytoskeletal dose response against puromycin aminonucleoside (PAN).

Results

Cells cultured in 3D micropatterns for up to 14 days show a significant reduction in morphometric variability compared to unpatterned controls. During differentiation, micropatterned podocytes achieve cell cycle arrest faster and more robustly with reduced motility. Furthermore, the increased speed and the extent of cell cycle arrest is also observed in low serum, suggesting that the effects of morpho-mimetic culture are independent from biochemical stimuli. AFM elastography shows primarily a peripheral distribution of stiff actin fibers in micropatterned podocytes, mimicking in situ conditions. A cohesive cytoskeletal dose response was observed against PAN in the micropatterned cells only.

Conclusion

3D micropatterns increase the speed and efficiency of podocyte differentiation while reducing cell-to-cell variability by up to 5-fold. Through its increased reproducibility, our automated system allows for quantitative in vitro study of podocyte morphology, cytoskeleton and biomechanics in response to drugs and pathogens with high fidelity and reproducibility.

Funding

  • NIDDK Support